You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas: Central Nervous System
Nerlynx (neratinib) in Combination With Capecitabine or Paclitaxel Included in NCCN Guidelines as Treatment Option for Patients With Breast Cancer Brain Metastases
5 April 2018 - - US-based cancer care-focused company Puma biotechnology, Inc.'s (NASDAQ: PBYI) Nerlynx (neratinib) has been included as a recommended treatment option in the latest National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology Central Nervous System Cancers for breast cancer patients with brain metastases,.
The NCCN designated Nerlynx in combination with capecitabine as a category 2A treatment option and Nerlynx in combination with paclitaxel as a category 2B treatment option.
Use, as designated for breast cancer patients with brain metastases, is outside the FDA approved indication for Nerlynx and considered investigational.
NCCN, a not-for-profit alliance of 27 of the world's leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Puma biotechnology is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care.
The NCCN designated Nerlynx in combination with capecitabine as a category 2A treatment option and Nerlynx in combination with paclitaxel as a category 2B treatment option.
Use, as designated for breast cancer patients with brain metastases, is outside the FDA approved indication for Nerlynx and considered investigational.
NCCN, a not-for-profit alliance of 27 of the world's leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Puma biotechnology is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care.
Login
Related Headlines
Aetna Coverage Decision Extends Abbott's Pain Therapy Option in US
Emergent BioSolutions to acquire Adapt Pharma
E-Scape Bio Appoints Smith as President and Chief Executive Officer
PTC Therapeutics closes Agilis Biotherapeutics' acquisition